10x Genomics TXG

$ 14.14 3.89%

Quarterly report 2024-Q3
added 10-29-2024

10x Genomics Balance Sheet 2011-2024 | TXG

Annual Balance Sheet 10x Genomics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-264 M	-125 M	-505 M	-601 M	-394 M	-35.4 M	-37.3 M	-	-	-	-	-	-
Long Term Debt	83.8 M	86.1 M	76.8 M	57 M	19.8 M	25.5 M	6.34 M	-	-	-	-	-	-
Long Term Debt Current	11.5 M	9.04 M	5.13 M	5.94 M	9.88 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	123 M	312 M	166 M	-	-	-	-	-	-
Total Current Liabilities	127 M	131 M	110 M	118 M	63 M	-	-	-	-	-	-	-	-
Total Liabilities	224 M	223 M	201 M	190 M	186 M	344 M	188 M	-	-	-	-	-	-
Deferred Revenue	13.2 M	7.87 M	5.34 M	4.47 M	4.6 M	2.78 M	1.83 M	-	-	-	-	-	-
Retained Earnings	-1.28 B	-1.03 B	-863 M	-	-262 M	-231 M	-119 M	-	-	-	-	-	-
Total Assets	965 M	1.03 B	1.02 B	929 M	606 M	124 M	75.6 M	-	-	-	-	-	-
Cash and Cash Equivalents	359 M	220 M	587 M	664 M	424 M	65.1 M	47.9 M	-	-	-	-	-	-
Book Value	741 M	806 M	818 M	739 M	420 M	-220 M	-113 M	-	-	-	-	-	-
Total Shareholders Equity	741 M	806 M	818 M	739 M	420 M	-220 M	-113 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet 10x Genomics

	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	76.5 M	78.7 M	81 M	-	-	92.8 M	86.1 M	-	91 M	93.5 M	76.8 M	75.7 M	65.9 M	66.3 M	-	-	-	-	19.8 M	19.8 M	19.8 M	19.8 M	25.5 M	25.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	215 M	206 M	204 M	-	-	212 M	223 M	-	218 M	197 M	201 M	190 M	193 M	202 M	190 M	190 M	190 M	190 M	186 M	186 M	186 M	186 M	101 M	101 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	17.8 M	16.4 M	14.3 M	-	-	8.53 M	7.87 M	-	6.47 M	5.43 M	5.34 M	5.5 M	5.27 M	4.48 M	4.47 M	4.47 M	4.47 M	4.47 M	3.3 M	3.3 M	3.3 M	3.3 M	2.4 M	2.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.42 B	-1.38 B	-1.34 B	-	-	-1.08 B	-1.03 B	-	-970 M	-906 M	-863 M	-845 M	-828 M	-817 M	-805 M	-805 M	-805 M	-805 M	-262 M	-262 M	-262 M	-262 M	-231 M	-231 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	938 M	930 M	923 M	-	-	1.01 B	1.03 B	-	1 B	1 B	1.02 B	991 M	978 M	954 M	929 M	929 M	929 M	929 M	606 M	606 M	606 M	606 M	124 M	124 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	398 M	380 M	356 M	315 M	331 M	340 M	227 M	-	282 M	320 M	596 M	609 M	649 M	644 M	689 M	689 M	689 M	689 M	424 M	427 M	476 M	476 M	65.1 M	65.1 M	-	-	47.9 M	-	-	-	41.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	723 M	724 M	719 M	-	-	802 M	806 M	-	784 M	807 M	818 M	800 M	785 M	752 M	739 M	739 M	739 M	739 M	420 M	420 M	420 M	420 M	23.3 M	23.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	723 M	724 M	719 M	745 M	793 M	802 M	806 M	-	784 M	807 M	818 M	800 M	785 M	752 M	739 M	739 M	739 M	739 M	420 M	420 M	420 M	420 M	-220 M	-220 M	-132 M	-127 M	-113 M	-	-	-	-96.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency